Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma

Neuroendocrinology Letters

Volumn 32, Issue SUPPL. 1, 2011, Pages 101-116

  Poljakova, Jitka ^a   Hrebackova, Jana ^b   Dvorakova, Marketa ^a   Moserova, Michaela ^a   Eckschlager, Tomas ^b   Hrabeta, Jan ^b   Göttlicherova, Marketa ^a   Kopejtkova, Barbora ^a   Frei, Eva ^c   Kizek, Rene ^d   Stiborova, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d MENDEL UNIVERSITY IN BRNO   (Czech Republic)

Author keywords

Cytotoxicity; DNA adduct; Ellipticine; Neuroblastoma; Trichostatin A; Valproic acid

Indexed keywords

CYCLOOXYGENASE 1; CYTOCHROME B5; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; DRUG METABOLITE; ELLIPTICINE; GLYCOPROTEIN P; LACTOPEROXIDASE; PEROXIDASE; PHOSPHORUS 32; TRICHOSTATIN A; VALPROIC ACID;

ARTICLE; BREAST ADENOCARCINOMA; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA MODIFICATION; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MICROSOME; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

EID: 84857375705     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Aimova D, Svobodova L, Kotrbova V, Mrazova B, Hodek P, Hudecek J, et al. (2007) The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos 35: 1926-1934. (Pubitemid 47481588)
2. Auclair C (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259: 1-14.
3. Bedrnicek J, Vicha A, Jarosova M, Holzerova M, Cinatl J Jr, Michaelis M, et al. (2005) Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma 52: 415-419. (Pubitemid 41406690)
4. Blaheta RA and Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492-511.
5. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, et al. (2007) Valproic acid inhibits adhesion of vincristine-and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 96: 1699-1706. (Pubitemid 46847201)
6. Blaheta RA, Nau H, Michaelis M and Cinatl J Jr (2002) Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 9: 1417-1433. (Pubitemid 34823024)
7. Bolden JE, Peart MJ and Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. (Pubitemid 44348499)
8. Borek-Dohalska L, Frei E and Stiborova M (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69: 603-615. (Pubitemid 38526511)
9. Bort R, Gomez-Lechon MJ, Castell JV and Jover R (2004) Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. Arch Biochem Biophys 426: 63-72. (Pubitemid 38595130)
10. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
11. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, et al. (2006) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. J Endocrinol 191: 465-472. (Pubitemid 44830622)
12. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. (2007) Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 35: 1032-1041. (Pubitemid 46956421)
13. Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B and Schwabe D (1997) Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-Cancer Drugs 8: 958-963. (Pubitemid 28027094)
14. Cinatl J Jr, Cinatl J, Kotchetkov R, Vogel JU, Woodcock BG, Matousek J, et al. (1999) Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis. Int J Oncol 15: 1001-1009.
15. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, et al. (1996) Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anti-Cancer Drugs 7: 766-773. (Pubitemid 26388767)
16. Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E and Altschuler Y (2006) White HS, Bialer M. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol 149: 250-260. (Pubitemid 44453425)
17. Fernandez N, Roy M and Lesca P (1988) Binding characteristics of Ah receptors from rats and mice before and after separation from hepatic cytosols. 7-Hydroxyellipticine as a competitive antagonist of cytochrome P-450 induction. Eur J Biochem 172: 585-592. (Pubitemid 18076477)
18. Fisher JE, Nau H and Löscher W (1991) Alterations in the renal excretion of valproate and its metabolites after chronic treatment. Epilepsia 32: 146-150.
19. Fosse P, Rene B, Charra M, Paoletti C and Saucier JM (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42: 590-595. (Pubitemid 23027620)
20. Frei E, Bieler CA, Arlt VM, Wiessler M and Stiborova M (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64: 289-295. (Pubitemid 34775308)
21. Froelich-Ammon SJ, Patchan MW, Osheroff N and Thompson RB (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270: 14998-15004.
22. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A and Frühwald MC (2007) Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120: 1787-1794. (Pubitemid 46399367)
23. Gasiewicz TA, Kende RS, Rucci G, Whitney B and Willey JJ (1996). Analysis of structural requirements for Ah receptor antagonist activity: Ellipticines, flavones, and related compounds. Biochem Pharmacol. 52: 1787-830.
24. Gupta M, Gupta YK, Agarwal S, Aneja S and Kohli K (2004) A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol 58: 542-547. (Pubitemid 39540459)
25. Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, et al. (2005) Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. Bioorg Med Chem Lett 15: 1283-1287. (Pubitemid 40268976)
26. Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL and Gross N (2002) Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 21: 6132-6137.
27. Hrebackova J, Hrabeta J and Eckschlager T (2010) Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 11: 361-379.
28. Hrebackova J, Poljakova J, Eckschlager T, Hrabeta J, Prochazka P, Smutny S et al. (2009) Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdisc Toxicol 2: 205-210.
29. Huang Y, Blower PE, Yang C, Barbacioru C, Dai Z, Zhang Y, et al. (2005) Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1. Pharmacogenomics J 5: 112-125. (Pubitemid 40468118)
30. Isojärvi JI, Turkka J, Pakarinen AJ, Kotila M, Rättyä J and Myllylä VV (2001) Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 42: 930-934.
31. Kerzee JK and Ramos KS (2001) Constitutive and inducible expression of Cyp1a1 and Cyp1b1 in vascular smooth muscle cells. Circ Res 89: 573-582.
32. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Yand Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300. (Pubitemid 37413470)
33. 5 shifts oxidation of anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation metabolites, thereby modulating its pharmacological efficacy. Biochem Pharmacol. 82(6): 669-80.
34. Lanza F, Latorraca A, Moretti S, Castagnari B, Ferrari L and Castoldi G (1997) Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells, Cytometry 30: 134-144. (Pubitemid 27296734)
35. Marchion DC, Bicaku E, Daud Al, Sullivan DM and Munster PN (2005a) Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815-3822. (Pubitemid 40616361)
36. Marchion DC, Bicaku E, Daud AI, Sullivan DM and Munster PN (2005b) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4: 1993-2000. (Pubitemid 43056982)
37. Maris JM and Mathay KK (1999) Molecular biology of neuroblastomas. J Clin Oncol 17: 2264-2279.
38. Marks PA, Miller T and Richon VM (2003) Histone deacetylases. Curr Opin Pharmacol 3: 344-351. (Pubitemid 36908937)
39. Marks PA, Richon VM, Miller T and Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168. (Pubitemid 39140958)
40. Martinkova E, Dontenwill M, Frei E and Stiborova M (2009). Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett. 30 (Suppl): 60-66.
41. Martinkova E, Maglott A, Leger, DY, Bonnet D, Stiborova M, Takeda K, et al. (2010). α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 127: 1240-1248.
42. McCormick DL, Adamowski CB, Fiks A and Moon RC (1981) Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea, Cancer Res 41: 1690-1694. (Pubitemid 11114558)
43. Michaelis M, Doerr HW and Cinatl J Jr (2007) Valproic acid as anti-cancer drug. Curr Pharm Des 13: 3378-3393. (Pubitemid 350201672)
44. Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J Jr (2004) Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799.
45. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, et al. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25: 1820-1829. (Pubitemid 21908374)
46. Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM (2004) Wilms' tumor and neuroblastoma. Acta Paediatr Suppl 93: 78-85. (Pubitemid 38570264)
47. Moserova M, Kotrbova V, Rupertova M, Naiman K, Hudecek J, Hodek P, et al. (2008). Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett. 29: 728-732.
48. Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61: 246-255.
49. Poljakova J, Dracinsky M, Frei E., Hudecek J and Stiborova M (2006) The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect Czech Chem Commun. 71: 1169-1185. (Pubitemid 44432311)
50. Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, et al. (2009) The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol. 77: 1466-1479.
51. Poljakova J, Forsterova K, Sulc M, Frei E and Stiborova M (2005) Oxidation of ellipticine by peroxidases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149: 449-453.
52. Poljakova J, Frei E, Gomez JE, Aimova D, Eckschlager T, Hrabeta J, et al. (2007) DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 252: 270-279. (Pubitemid 46809792)
53. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29: 413-580. (Pubitemid 27293618)
54. Rogiers V, Akrawi M, Vercruysse A, Phillips IR and Shephard EA (1995) Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases. Eur J Biochem 231: 337-343.
55. Rogiers V, Callaerts A, Vercruysse A, Akrawi M, Shephard EA and Phillips IR (1992) Effects of valproate on xenobiotic biotransformation in rat liver. In vivo and in vitro experiments. Pharm Weekbl Sci 4: 127-131.
56. Santini V, Gozzini A and Ferrari G (2007) Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 8: 383-393.
57. 5. Pharmacol Ther 97: 139-152.
58. Schwab M (1999) Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Naturwissenschaften 86: 71-78.
59. Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL and Lown JW (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33: 10271-10285. (Pubitemid 24281792)
60. Stiborova M, Arlt VM, Henderson CJ, Wolf CR, Kotrbova V, Moserova M, et al. (2008). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol. 226: 318-27. (Pubitemid 351172414)
61. Stiborova M, Bieler CA, Wiessler M and Frei E (2001).The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 62: 1675-1684. (Pubitemid 34033654)
62. Stiborova M, Borek-Dohalska L, Kotrbova V, Kukackova K, Janouchova K, Rupertova M, et al. (2006a). Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - Similarity between human and rat systems. Gen Physiol Biophys 25: 245-261. (Pubitemid 44857439)
63. Stiborova M, Breuer A, Aimova D, Stiborova-Rupertova M, Wiessler M and Frei E (2003a). DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107: 885-890. (Pubitemid 37429828)
64. Stiborova M, Martinek V, Rydlova H, Hodek P and Frei E (2002). Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res 62: 5678-5684. (Pubitemid 35204721)
65. Stiborova M, Martinek V, Rydlova H, Koblas T and Hodek P (2005). Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 220: 145-154. (Pubitemid 40568771)
66. Stiborova M, Martinek V, Schmeiser HH and Frei E (2006b). Modulation of CYP1A1-mediated oxidation of carcinogenic azo dye Sudan I and its binding to DNA by cytochrome b5. Neuro Endocrinol Lett. 27 (Suppl 2): 35-39 (Pubitemid 46534333)
67. Stiborova M, Moserova M, Mrazova B, Kotrbova V and Frei E (2010) Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. Neuro Endocrino. Lett 31 (Suppl. 2): 26-35.
68. Stiborova M, Poljakova J, Ryslava H, Dracinsky M, Eckschlager T and Frei E (2007a). Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 120: 243-251. (Pubitemid 44956832)
69. Stiborova M, Rupertova M, Aimova D, Ryslava H and Frei E (2007b) Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60. (Pubitemid 46777068)
70. Stiborova M, Rupertova M and Frei E (2011) Cytochrome P450and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta 1814: 175-185.
71. Stiborova M, Rupertova M, Schmeiser HH and Frei E (2006c) Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 13-23.
72. Stiborova M, Sejbal J, Borek-Dohalska L, Poljakova J, Forsterova K, Rupertova M et al. (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res. 64: 8374-8380. (Pubitemid 39496831)
73. Stiborova M, Stiborova-Rupertova M, Borek-Dohalska L, Wiessler M and Frei E (2003b) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol. 16: 38-47. (Pubitemid 36139409)
74. Voigt A, Hartmann P and Zintl F (2000) Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. Cell Adhes Commun 7: 423-440. (Pubitemid 30265258)
75. Wen X, Wang JS, Kivistö KT, Neuvonen PJ and Backman JT (2001) In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 52: 547-553.
76. Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, et al. 2007. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67: 1716-1724. (Pubitemid 46383398)